Advancements in Essential Reagents and Automation are Driving Revolutionary Change and Boosting Growth Opportunities
This study provides an overview of the global blood group typing industry, which is expected to witness significant growth, driven by factors like increased public awareness, improved healthcare infrastructure, government initiatives, and rising per capita income. The increasing prevalence of diseases associated with blood, such as sickle cell anemia, thalassemia, lymphoma, leukemia, and hemophilia, is also supporting the growth of blood group typing.
Technological advances, including automated analyzers and antiglobulin screening tools, are revolutionizing clinical outcomes and enhancing blood compatibility. Major market players are prioritizing research and development (R&D) investments to offer innovative devices, improve safety, enhance storage duration, and promote industry growth. Strategic partnerships and alliances are becoming more popular in this competitive environment, allowing industry participants to broaden their product offerings and improve their worldwide presence.
The study offers relevant forecasts for this industry by region (North America, Europe, Asia-Pacific, and the rest of the world), test type (ABO blood tests & Rh typing, antibody screening, HLA typing, antigen typing, and others), and end users (hospitals, blood banks, clinical laboratories, and others). It analyzes the factors driving and restraining this industry and identifies the growth opportunities emerging from the changes in this space for stakeholders and market players to leverage. The base year is 2023, and the forecast period is from 2024 to 2028.
